AR013618A1 - Metodo y composiciones para la distribucion y expresion de acidos nucleicos de interferon - Google Patents
Metodo y composiciones para la distribucion y expresion de acidos nucleicos de interferonInfo
- Publication number
- AR013618A1 AR013618A1 ARP970104830A ARP970104830A AR013618A1 AR 013618 A1 AR013618 A1 AR 013618A1 AR P970104830 A ARP970104830 A AR P970104830A AR P970104830 A ARP970104830 A AR P970104830A AR 013618 A1 AR013618 A1 AR 013618A1
- Authority
- AR
- Argentina
- Prior art keywords
- interferon
- compositions
- expression
- distribution
- nucleic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Se provee una composicion que comprende a un vector, dicho vector comprende a un segmento de ácido nucleico que codifica a un polipéptido de interferonalfa; el segmento de ácido nucleico está operativamente enlazado a un promotor específico para untejido de interés. Asimismo se proveen composicionesfarmacéuticas y métodos para proporcionar un polipéptido de interferon alfa a un tejido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73381596A | 1996-10-18 | 1996-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR013618A1 true AR013618A1 (es) | 2001-01-10 |
Family
ID=24949214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970104830A AR013618A1 (es) | 1996-10-18 | 1997-10-17 | Metodo y composiciones para la distribucion y expresion de acidos nucleicos de interferon |
Country Status (20)
Country | Link |
---|---|
EP (2) | EP1591528A3 (es) |
JP (2) | JP2001502540A (es) |
KR (1) | KR20000049243A (es) |
AR (1) | AR013618A1 (es) |
AU (1) | AU4808097A (es) |
BR (1) | BR9712362A (es) |
CA (1) | CA2269100A1 (es) |
CZ (1) | CZ131699A3 (es) |
DE (1) | DE932679T1 (es) |
ES (1) | ES2136583T1 (es) |
HU (1) | HUP9904219A2 (es) |
ID (1) | ID24500A (es) |
IL (1) | IL129387A0 (es) |
NO (1) | NO991839L (es) |
NZ (1) | NZ335134A (es) |
PL (1) | PL332856A1 (es) |
SK (1) | SK50699A3 (es) |
TR (1) | TR199901190T2 (es) |
WO (1) | WO1998017801A1 (es) |
ZA (1) | ZA979295B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9912925D0 (en) * | 1999-06-03 | 1999-08-04 | Angeletti P Ist Richerche Bio | Adenoviral vectors encoding interferon and their use in gene therapy |
US8058248B2 (en) * | 2001-04-26 | 2011-11-15 | The United States Of America As Represented By The Secretary Of Agriculture | Foot and mouth disease virus vaccine comprising interferons |
JP4563171B2 (ja) | 2002-05-24 | 2010-10-13 | シェーリング コーポレイション | 中和ヒト抗igfr抗体 |
US7326567B2 (en) | 2003-11-12 | 2008-02-05 | Schering Corporation | Plasmid system for multigene expression |
AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
CN1893981B (zh) | 2003-12-10 | 2011-03-23 | 坎基股份有限公司 | 用于治疗干扰素耐药性肿瘤的方法和组合物 |
JP2008521907A (ja) | 2004-12-03 | 2008-06-26 | シェーリング コーポレイション | 抗igf1r治療について患者を予め選択するためのバイオマーカー |
KR101449587B1 (ko) | 2006-09-14 | 2014-10-10 | 메드제닉스 메디칼 이스라엘 리미티드 | 장기 지속형 약물 제형 |
US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
EP2114459B1 (en) | 2007-02-23 | 2013-09-25 | Her Majesty The Queen, In Right Of Canada, As Represented by the Minister of National Defence | Recombinant viral vectors for prevention and protection against alphavirus infection |
CA2764759A1 (en) | 2009-06-09 | 2010-12-16 | Defyrus, Inc. | Administration of interferon for prophylaxis against or treatment of pathogenic infection |
CN103260649A (zh) | 2010-06-15 | 2013-08-21 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
WO2018178215A1 (en) | 2017-03-31 | 2018-10-04 | Accanis Biotech F&E Gmbh & Co Kg | Prevention and treatment of non-melanoma skin cancer (nmsc) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4238778C2 (de) * | 1992-11-12 | 1995-11-02 | Max Delbrueck Centrum | Vektor zur Expression von therapeutisch relevanten Genen |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
ATE314482T1 (de) * | 1993-10-25 | 2006-01-15 | Canji Inc | Rekombinante adenoviren-vektor und verfahren zur verwendung |
US5830686A (en) * | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
DE4407859C1 (de) * | 1994-03-04 | 1995-03-02 | Max Planck Gesellschaft | Vektor für die leberspezifische Gentherapie |
JP4216350B2 (ja) * | 1994-09-19 | 2009-01-28 | 大日本住友製薬株式会社 | 動物細胞感染用の組換えdnaウイルスベクター |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
-
1997
- 1997-10-16 WO PCT/US1997/017928 patent/WO1998017801A1/en not_active Application Discontinuation
- 1997-10-16 EP EP05013342A patent/EP1591528A3/en not_active Withdrawn
- 1997-10-16 SK SK506-99A patent/SK50699A3/sk unknown
- 1997-10-16 CZ CZ991316A patent/CZ131699A3/cs unknown
- 1997-10-16 BR BR9712362-5A patent/BR9712362A/pt not_active Application Discontinuation
- 1997-10-16 NZ NZ335134A patent/NZ335134A/en unknown
- 1997-10-16 TR TR1999/01190T patent/TR199901190T2/xx unknown
- 1997-10-16 ES ES97910794T patent/ES2136583T1/es active Pending
- 1997-10-16 DE DE0932679T patent/DE932679T1/de active Pending
- 1997-10-16 ZA ZA9709295A patent/ZA979295B/xx unknown
- 1997-10-16 IL IL12938797A patent/IL129387A0/xx unknown
- 1997-10-16 KR KR1019990703347A patent/KR20000049243A/ko not_active Application Discontinuation
- 1997-10-16 JP JP10519400A patent/JP2001502540A/ja not_active Withdrawn
- 1997-10-16 CA CA002269100A patent/CA2269100A1/en not_active Abandoned
- 1997-10-16 EP EP97910794A patent/EP0932679A1/en not_active Ceased
- 1997-10-16 ID IDW990218D patent/ID24500A/id unknown
- 1997-10-16 AU AU48080/97A patent/AU4808097A/en not_active Abandoned
- 1997-10-16 HU HU9904219A patent/HUP9904219A2/hu unknown
- 1997-10-16 PL PL97332856A patent/PL332856A1/xx unknown
- 1997-10-17 AR ARP970104830A patent/AR013618A1/es not_active Application Discontinuation
-
1999
- 1999-04-16 NO NO991839A patent/NO991839L/no not_active Application Discontinuation
-
2008
- 2008-08-20 JP JP2008212260A patent/JP2008301832A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1591528A3 (en) | 2005-11-16 |
ZA979295B (en) | 1998-04-20 |
TR199901190T2 (xx) | 1999-07-21 |
JP2001502540A (ja) | 2001-02-27 |
JP2008301832A (ja) | 2008-12-18 |
CZ131699A3 (cs) | 1999-07-14 |
ID24500A (id) | 2000-07-20 |
HUP9904219A2 (hu) | 2000-12-28 |
NZ335134A (en) | 2001-05-25 |
WO1998017801A1 (en) | 1998-04-30 |
SK50699A3 (en) | 2000-05-16 |
NO991839D0 (no) | 1999-04-16 |
EP1591528A2 (en) | 2005-11-02 |
EP0932679A1 (en) | 1999-08-04 |
PL332856A1 (en) | 1999-10-25 |
IL129387A0 (en) | 2000-02-17 |
DE932679T1 (de) | 2000-03-09 |
KR20000049243A (ko) | 2000-07-25 |
NO991839L (no) | 1999-06-15 |
BR9712362A (pt) | 1999-08-31 |
AU4808097A (en) | 1998-05-15 |
ES2136583T1 (es) | 1999-12-01 |
CA2269100A1 (en) | 1998-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR013618A1 (es) | Metodo y composiciones para la distribucion y expresion de acidos nucleicos de interferon | |
EP0722461A4 (en) | EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF CYTOPLASM WITHOUT HEAD SEQUENCE | |
AR004668A1 (es) | Un acido nucleico aislado purificado, un vector de expresion recombinante que lo comprende, una celula que comprende dicho vector, un metodo para laproduccion de un polipeptido de h.pylori, una composicion de vacuna, el uso de dicha composicion para preparar medicamentos, un polipeptido purificado de h. | |
ES2073571T3 (es) | Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas. | |
KR920701452A (ko) | 프라세싱 부위에 인접한 음전하를 띤 아미노산을 함유하는 이스트 프라세싱 시스템 | |
AR017510A1 (es) | Polinucleotido aislado o recombinante, vector de expresion, celula huesped, metodo para preparar un polipeptido antigenico, metodo y equipo para ladeteccion de un polinucleotido, compuesto de union, metodo de empleo del compuesto de union, polipeptido antigenico aislado o substancialmente puro, ymet | |
ES553935A0 (es) | Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante. | |
ES2072900T3 (es) | Expresion elevada de proteinas en levadura. | |
KR850004273A (ko) | 안정성이 증대된 재조합 감마 인터페론 및 그의 제조방법 | |
ATE182901T1 (de) | Für androgen-rezeptor-protein kodierende dna | |
ES2137928T3 (es) | Polipeptidos del dominio de union a fibrina y usos y metodos para producirlos. | |
HU9200548D0 (en) | Improved activity process of recombined proteins | |
RU94036776A (ru) | Домен ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена ингибитора протеазы | |
DE3584579D1 (de) | Herstellung von polypeptiden mit human-gammainterferon-aktivitaet. | |
IL85020A0 (en) | Pancreatic secretory trypsin inhibitor and variants thereof,process expression vector and recombinant host therefor and pharmaceutical compositions containing it | |
AU575843B2 (en) | Growth hormone releasing peptides | |
DE3688324D1 (de) | Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel. | |
AR009600A1 (es) | Secuencia de acido nucleico y aminoacidos relacionados con helicobacter pylori y composiciones de vacuna de la misma. | |
DK0652903T3 (da) | Nyt humant rekombinant gammainterferon | |
Goldstone et al. | Amino acid sequence of whale heart cytochrome c | |
DK0946590T3 (da) | Dihydroxypropylcysteinpeptid og middel, der indeholder dette peptid | |
KR890700673A (ko) | 돼지 성장호르몬 아날로그 | |
DE59209915D1 (de) | Verfahren zur Herstellung von Polypeptiden mit Prourokinase-Aktivität | |
FI913405A (fi) | In vitro preparering av fusionsproteiner. | |
Katayama et al. | Specific cleavage of reduced and S-carboxamidomethylated neurophysin II by the collagenase of Clostridium histolyticum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |